Skip to main content
logo
Stevanato Group S.p.A. (STVN)
NYSE: STVN · Real-Time Price · USD
21.71
+0.51 (2.41%)
Aug 19, 2026, 4:00 PM EDT - Market closed

Revenue by Geography

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
EMEA Revenue
-690.34M667.83M
APAC Revenue
-101.48M96.24M
North America Revenue
-362.06M308.95M
South America Revenue
-32.40M31.02M
Revenue (Total)
1.23B1.19B1.10B

Revenue

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Biopharmaceutical and Diagnostic Solutions Revenue
1.09B1.04B933.74M
Engineering Revenue
136.25M148.11M170.29M
Revenue (Other)
-5.00K--
Revenue (Total)
1.23B1.19B1.10B

Gross Profit

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Biopharmaceutical and Diagnostic Solutions Gross Profit
336.09M328.15M268.78M
Engineering Gross Profit
34.06M31.02M56.17M
Eliminations from Gross Profit
-12.75M-15.29M-22.63M
Gross Profit (Other)
-10.00K--
Gross Profit (Total)
357.39M343.88M302.32M

EBIT

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Biopharmaceutical and Diagnostic Solutions Operating Profit
218.40M220.43M165.64M
Engineering Operating Profit
11.61M9.33M33.10M
Eliminations from Operating Profit
-29.40M-30.95M-37.59M
Operating Income (Other)
3.00K--
Operating Income (Total)
200.61M198.80M161.14M

Key Performance Indicators

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Backlog
871.00M853.00M